Potential therapeutic effects of induced pluripotent stem cells on induced salivary gland cancer in experimental rats

Salivary gland neoplasms exhibit complex histopathology in a variety of tumor types and treatment options depend largely on the stage of the cancer. Induced pluripotent stem cells (iPS) have been investigated for treating induced salivary gland cancer and for restoring salivary gland function. We investigated iPS treatment for salivary gland cancer both in vitro and in vivo. For our study in vitro, we re-programmed human skin fibroblasts to form iPS cells using a plasmid containing Oct4, Sox2, L-MYC and LIN28. For our study in vivo, we used 30 white male albino rats divided into the following groups of 10: group 1 (control): rats were injected with phosphate-buffered saline (PBS), group 2 induced squamous cell carcinoma (SCC): rat submandibular glands were injected with squamous carcinoma cells (SCC), group 3 (induced SCC/iPS): SCC treated rats treated with 5 × 106 iPS cells. Submandibular glands from rats of all groups were examined histologically and real time PCR was performed for amylase, and COX I and COX II gene expression. We confirmed that submandibular gland specimens included tumor tissue before starting treatment with iPS. iPS treated cases exhibited regeneration of salivary glands, although minor degenerative and vascularization changes remained. The acinar cells regained their proper organization, but continued to exhibit abnormal activity including hyperchromatism. iPS cells may be useful for treating salivary gland carcinomas.     

Hepatic effects of long‐term tamoxifen administration to cycling female rats

The metabolic implications of tamoxifen (TAM) used as preventive therapy of young premenopausal women with high risk of breast cancer is unknown. To unravel this problem, an animal model of long‐term TAM administration to cycling young adult female rats was used to evaluate its effects in the liver. Body weight and food consumption were monitored, and at the end of the study, both parameters were lower in TAM‐treated rats. Biochemical measurements showed that the TAM administration induced alterations in serum levels of liver enzymes when compared with control rats at different stages of the estrous cycle. In TAM‐treated rats, lower glycogen storage was observed in hepatocytes close to the portal areas and pericentrolobular cells had a higher concentration of glycogen. Liver sections of TAM‐treated rats presented mild steatosis—a high percentage of area occupied by lipid droplets in the hepatocytes. These results point to metabolic changes upon long‐term TAM therapy.     

6周不同强度间歇性运动对肥胖大鼠体成分的影响*

目的:探讨不同强度间歇性运动对肥胖大鼠身体机能影响,为肥胖症的防治提供依据。方法:80只SD大鼠随机分成普通膳食组(n=20)和高脂膳食组(n=60),适应性喂养8周后,筛选普通膳食大鼠8只和高脂膳食肥胖大鼠32只,用于后续实验。将实验大鼠随机分为5组(n=8):普通对照组(CS),普通饲料喂养,不做任何运动;高脂安静组(HS):高脂饲料喂养,不作任何运动;高脂持续运动组(HC):进行60 min/d×5天/周×6周;高脂长时间低频率间歇性运动组(HLL):进行30 min/次×2次/天(间歇6 h)×5天/周×6周;高脂短时间高频率间歇性运动组(HSH):进行20 min/次×3次/天(间歇3 h)×5天/周×6周,各运动组大鼠在跑台上训练强度均为25 m/min。6周后,各组大鼠称重、检测RMR、FBG、TG等生化指标,并测量体脂及肌肉重量。结果:实验前,各组大鼠之间RMR、FBG、TG指标无统计学差异(P＞0.05);HSH、HLL、HC、HS组体重均明显高于CS组(P＜0.05)。实验后,HSH、HLL、HC组RMR均明显高于HS、CS组(P＜0.05),但HSH、HLL、HC组之间无显著性差异(P＞0.05);HS组体重高于CS组(P＜0.05),HSH、HLL、HC组体重明显低于HS组(P＜0.05),但三组之间无显著性差异(P＞0.05);HSH、HLL、HC组之间PF、EF、PF/W、EF/W均明显低于HS组(P＜0.01),而三者之间无统计学差异(P＞0.05);各组大鼠GM、QF均无显著性差异(P＞0.05),HSH、HLL、HC组之间GM/W、QF/W高于HS组(P＜0.05),而HSH、HLL、HC组之间无显著性差异(P＞0.05);HSH、HLL、HC组FBG、TG均明显低于CS、HS组(P＜0.05),但与HS组差异更显著(P＜0.01),而各训练组之间无显著性差异(P＞0.05)。结论:6周不同强度间歇性运动对肥胖大鼠体成分产生了良好的干预效果,且短时间高频率间歇性运动(HSH)效果可能更好。     

姜黄素及其类似物J7对2型糖尿病大鼠睾丸氧化应激损伤的干预作用*

目的: 研究姜黄素(CUR)及其类似物J7对糖尿病大鼠睾丸氧化应激损伤的干预作用。方法: 60只SD大鼠随机分组,其中10只作为正常(NC)组,余50只通过高脂饮食和腹腔注射链脲佐菌素诱导建立糖尿病大鼠模型,造模成功后将其再分为4组:糖尿病(DM,n=12)组、姜黄素治疗(CUR,n=10)组、J7高剂量治疗(J+,n=10)组、J7低剂量治疗(J-,n=10)组。CUR组大鼠每天予以姜黄素20 mg/kg灌胃治疗,J+及J-组分别予以J7 20 mg/kg、10 mg/kg灌胃治疗,8周后处死大鼠,测量各组大鼠体重、空腹血糖,羟胺法和硫代巴比妥酸法分别检测超氧化物歧化酶(SOD)活性和丙二醛(MDA)含量,Western blot法检测tNrf2、pNrf2、CAT、NQO1蛋白表达水平,qRT-PCR检测CAT、NQO1、HO1 mRNA表达水平,光镜下观察大鼠睾丸形态学改变,免疫组化检测Nrf2及CAT蛋白表达情况。结果: DM组血糖、MDA水平升高(P＜0.05),体重、SOD活性、pNrf2/tNrf2、CAT、NQO1蛋白及CAT、NQO1、HO1 mRNA水平均有下降(P＜0.05);光镜下见睾丸各级生精细胞减少、排列紊乱;免疫组化显示Nrf2蛋白核周表达量下降,CAT蛋白表达水平降低。经姜黄素及J7治疗后,三个治疗组的MDA水平均下降(P＜0.05),SOD活性、pNrf2/tNrf2、CAT、NQO1蛋白及NQO1、HO1 mRNA水平均上升(P＜0.05),J+及J-组血糖显著下降(P＜0.05),J+组CAT mRNA水平显著上升(P＜0.05);J+组pNrf2/tNrf2比值明显高于CUR组及J-组(P＜0.05),J+组CAT蛋白水平也明显高于J-组(P＜0.05),其余指标在三个治疗组间不具有显著性差异。光镜下见三个治疗组睾丸形态学病变减轻;免疫组化显示Nrf2蛋白核周表达量上升,CAT蛋白表达水平升高。提示高剂量J7抗糖尿病大鼠睾丸的氧化应激损伤的能力较强。结论: 姜黄素及J7可在一定程度上对抗糖尿病大鼠睾丸的氧化应激损伤,其机制可能与Nrf2-ARE信号通路的激活相关。     

C肽对糖尿病大鼠肾脏的影响

比较C肽和胰岛素对大鼠糖尿病肾病的治疗作用。方法:选取Wistar大鼠40只,分为正常对照组(NG组)和糖尿病组(DM组),糖尿病组链脲佐菌素诱发大鼠成模后,随机分为三组:糖尿病组(DM组)、胰岛素组(IG组)和C肽组(ICG组)。治疗8周后测定各组大鼠24小时尿白蛋白排泄率(UAER)、肾重/体重,并观察糖尿病大鼠肾脏超微结构变化。结果:24小时尿白蛋白排泄率:糖尿病组明显增加,C肽组明显低于糖尿病组和胰岛素组,差异具有显著性。大鼠肾脏超微结构变化:各组大鼠肾小球截面积、肾小球平均体积(MGV)、细胞外基质/肾小球截面积比值、细胞外基质截面积、肾小球基底膜厚度相比,糖尿病组明显升高,C肽组较胰岛素组和糖尿病组明显下降,差异具有显著性。结论:C肽治疗可以降低24小时尿白蛋白排泄率,改善糖尿病大鼠肾脏超微结构病变。     

Applications of a new subspace clustering algorithm (COSA) in medical systems biology

A novel clustering approach named Clustering Objects on Subsets of Attributes (COSA) has been proposed (Friedman and Meulman, (2004). Clustering objects on subsets of attributes. J. R. Statist. Soc. B 66, 1–25.) for unsupervised analysis of complex data sets. We demonstrate its usefulness in medical systems biology studies. Examples of metabolomics analyses are described as well as the unsupervised clustering based on the study of disease pathology and intervention effects in rats and humans. In comparison to principal components analysis and hierarchical clustering based on Euclidean distance, COSA shows an enhanced capability to trace partial similarities in groups of objects enabling a new discovery approach in systems biology as well as offering a unique approach to reveal common denominators of complex multi-factorial diseases in animal and human studies. Doris Damian, Matej Orešič, and Elwin Verheij contributed equally to this work.     

Effects of tert-butyl acetate on maternal toxicity and embryo-fetal development in Sprague-Dawley rats

This study investigated the potential adverse effects of tert-butyl acetate (TBAc) on maternal toxicity and embryo-fetal development after maternal exposure of pregnant rats from gestational days 6 through 19. TBAc was administered to pregnant rats by gavage at 0, 400, 800, and 1,600 mg/kg/day. All dams were subjected to a Caesarean section on day 20 of gestation, and their fetuses were examined for any morphological abnormalities. At 1,600 mg/kg, maternal toxicity manifested as increases in the incidence of clinical signs and death, lower body weight gain and food intake, increases in the weights of adrenal glands and liver, and a decrease in thymus weight. Developmental toxicity included a decrease in fetal weight, an increase in the incidence of skeletal variation, and a delay in fetal ossification. At 800 mg/kg, only a minimal developmental toxicity, including an increase in the incidence of skeletal variation and a delay in fetal ossification, were observed. In contrast, no adverse maternal or developmental effects were observed at 400 mg/kg. These results show that a 14-day repeated oral dose of TBAc is embryotoxic at a maternally toxic dose (i.e., 1,600 mg/kg/day) and is minimally embryotoxic at a nonmaternally toxic dose (i.e., 800 mg/kg/day) in rats. However, no evidence for the teratogenicity of TBAc was noted in rats. It is concluded that the developmental findings observed in the present study are secondary effects to maternal toxicity. Under these experimental conditions, the no-observed-adverse-effect level of TBAc is considered to be 800 mg/kg/day for dams and 400 mg/kg/day for embryo-fetal development.     

Inhalation developmental neurotoxicity study of ethylbenzene in Crl-CD rats

BACKGROUND: This study was conducted to evaluate the potential adverse effects of whole-body inhalation exposure of F0 and F1 parental animals from a 2-generation reproduction study of ethylbenzene on nervous system functional and/or morphologic end points in the F2 offspring from four groups of male and female Crl:CD (SD)IGS BR rats. METHODS: Thirty rats/sex/group for F0 and 25/sex/group for F1 were exposed to 0, 25, 100, and 500 ppm ethylbenzene for six hours daily for at least 70 consecutive days prior to mating for the F0 and F1 generations. Inhalation exposure for the F0 and F1 females continued throughout mating and gestation through Gestation Day (GD) 20. On lactation days (LD) 1-4, the F0 and F1 females received no inhalation exposure, but instead were administered ethylbenzene in corn oil via oral gavage at dosages estimated to result in similar internal maternal exposure based upon PBPK modeling estimates (0, 26, 90, and 342 mg/kg/day, respectively, divided into three equal doses, approximately two hours apart). Inhalation exposure of the F0 and F1 females was reinitiated on LD 5 and continued through weaning on postnatal day (PND) 21. Survival, body weights, and physical landmarks were assessed in selected F2 offspring. Neurobehavioral development of one F2-generation treatment derived offspring/sex/litter was assessed in a functional observational battery (FOB; PND 4, 11, 22, 45, and 60), motor activity sessions (PND 13, 17, 21, and 61), acoustic startle testing (PND 20 and 60), a Biel water maze learning and memory task (initiated on PND 26 or 62), and in evaluations of whole-brain measurements and brain morphometric and histologic assessments (PND 21 and 72). RESULTS: There were no adverse effects on reproductive performance in either the F0 or F1 parental generations exposed to up to 500 ppm ethylbenzene [Faber et al. Birth Defects Res Part B 77:10-21, 2006]. In the current developmental neurotoxicity component, parental ethylbenzene exposure did not adversely affect offspring survival, clinical condition, body weight parameters, or acquisition of developmental landmarks of the F2-generation treatment derived offspring. There were no alterations in FOB parameters, motor activity counts, acoustic startle endpoints, or Biel water maze performance in offspring attributed to parental ethylbenzene exposure. A few isolated instances of statistically significant differences obtained in the treatment-derived groups occurred sporadically, and were attributed to unusual patterns of development and/or behavior in the concurrent control group. There were no exposure-related differences in any neuropathology parameters in the F2-generation treatment derived offspring. CONCLUSIONS: The no observed adverse effect level (NOAEL) for maternal reproductive toxicity, developmental toxicity, and developmental neurotoxicity in this study was considered to be 500 ppm/342 mg/kg/day ethylbenzene, the highest exposure level tested in the study.     

Identification of drug-induced hyper- or hypoprolactinemia in the female rat based on general and reproductive toxicity study parameters

Observations associated with drug-induced hyper- or hypoprolactinemia in rat toxicology studies may be similar and include increased ovarian weight due to increased presence of corpora lutea. Hyperprolactinemia may be distinguished if mammary gland hyperplasia with secretion and/or vaginal mucification is observed. Reproductive toxicity study endpoints can differentiate hyper- from hypoprolactinemia based on their differential effects on estrous cycles, mating, and fertility. Although the manifestations of hyper- and hypoprolactinemia in rats generally differ from that in humans, mechanisms of drug-related changes in prolactin synthesis/release can be conserved across species and pathologically increased or decreased prolactin levels may compromise some aspect of reproductive function in all species.     

Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits

BACKGROUND: The developmental toxicity potential of vorinostat (suberoylanilide hydroxamic acid [SAHA], ZOLINZA), a potent inhibitor of histone deacetylase (HDAC), was assessed in Sprague-Dawley rats and Dutch Belted rabbits. HDAC inhibitors have been shown to mediate the regulation of gene expression, induce cell growth, cell differentiation, and apoptosis of tumor cells. Range-finding studies established oral dose levels of 5, 15, or 50 mg/kg/day and 20, 50, or 150 mg/kg/day in rats and rabbits, respectively. METHODS: Animals were dosed on Gestation Days 6-20 or 7-20, respectively, with litter/fetal parameters evaluated on GD 21 and 28, respectively. Separate studies evaluated toxicokinetic parameters at the mid- and high-dose levels. RESULTS: There was no maternal toxicity observed at the highest dose levels; however, hematology and serum biochemistry changes were characterized in the range-finding studies. Vorinostat did not induce morphological malformations in either rat or rabbit fetuses. In rats, drug-related developmental toxicity was observed only in the high-dose group and consisted of markedly decreased fetal weight and increases in fetuses with a limited number of skeletal variations. In rabbits, drug-related developmental toxicity was also observed only in the high-dose group and consisted of slightly decreased fetal weight and increases in fetuses with a short 13th rib and incomplete ossification of metacarpals. Maternal exposures to vorinostat based on AUC and Cmax values were comparable at the high-dose levels of both species. Rabbits tolerated higher dosages probably due to more extensive metabolism. Maternal concentrations of vorinostat were approximately 1,000-fold above the known in vitro HDAC inhibitory concentration. CONCLUSIONS: Review of previous work with valproic acid, another HDAC inhibitor, suggest that the developmental toxicity profiles of these 2 compounds are not the result of HDAC inhibition but involve other mechanisms.